merckwindow_web

MSD to launch Keytruda at half US list price in China

pharmafile | September 20, 2018 | News story | Business Services, Sales and Marketing BMS, China, MSD, global, keytruda, markets, pricing 

US pharma giant MSD will offer cutting edge cancer treatment Keytruda to Chinese patients at half the price at what it is sold for in the United States, according to the Beijing-based news organisation Caixin Global.

Keytruda, which was approved in China in July of this year, will cost 17,918 yuan (£1,981) for a 100mg/ 4ml dose when it is introduced to the world’s second largest pharmaceutical market later this year.

The reduced price thus marks the lowest price at which Keytruda is sold around the world, at 50% of the US price and 30% lower than that of neighbouring Hong Kong.

The move comes after BristolMyersSquibb cut the price of cancer treatment Opdivo after it was authorised by the China Food and Drug Administration in June for patients with locally advanced or metastatic non-small-cell lung cancer. The therapy, which became the first PD-1 inhibitor approved in China, comes with a list price of 9260 yuan (£1023).

MSD have also announced that they have developed a patient financial assistance program for Keytruda, which will increase access for the humanised antibody which is used in cancer immunotherapy.

Louis Goss

Related Content

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 …

Merck shares results for Keytruda in cervical cancer treatment

Merck, known as MSD outside of the US and Canada, has announced positive results from …

FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment

Merck, known as MSD outside of the US and Canada, has announced that the US …

Latest content